Total Testosterone (Total T)
Total testosterone measures the cumulative concentration of circulating bound and unbound testosterone synthesized by testicular Leydig cells and adrenal cortices.
Standard vs. Optimal Reference Rangesng/dL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
300 - 1000 ng/dL (Male), 15 - 70 ng/dL (Female)
General reference distribution across unselected commercial populations.
600 - 900 ng/dL (Morning Fasting Male)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Pulsatile hypothalamic GnRH stimulates pituitary LH secretion, prompting Leydig cell steroidogenesis via STAR-mediated cholesterol transport. Circulating testosterone is ~45% bound to SHBG, ~50% loosely bound to albumin, and ~2% free.
Differential Diagnosis
Elevated Levels (Total T High)
- •Exogenous testosterone administration
- •Testicular or adrenal steroid-secreting tumors
- •Polycystic Ovary Syndrome (in females)
Low Levels (Total T Low)
- •Primary hypogonadism (testicular failure, elevated LH/FSH)
- •Secondary hypogonadism (pituitary/hypothalamic dysfunction, low LH)
- •Severe visceral adiposity and insulin resistance
- •Chronic opioid or glucocorticoid use
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Blood draw must occur strictly between 7:00 AM and 9:00 AM to account for steep circadian cortisol and testosterone peaks. Ensure 8 hours of restful sleep prior; night shift work or sleep deprivation severely blunts endocrine pulsatility. Discontinue biotin supplements for 72 hours before thyroid or steroid testing to prevent false immunoassay results. For reproductive hormones in premenopausal females, precisely document the day of the menstrual cycle (Day 3 for baseline follicular, Day 21 for luteal).
Reflexive Testing Protocol:
- Free Hormone Equilibrium Dialysis or LC-MS/MS assay for direct bioavailable hormone quantification
- Pituitary trophic hormone panel (TSH, LH, FSH, ACTH, Prolactin) to differentiate primary vs central secondary endocrinopathies
- Autoantibody quantification (Thyroid Peroxidase Antibodies, Thyroglobulin Antibodies, 21-Hydroxylase Antibodies)
- Pelvic, testicular, or thyroid high-resolution ultrasound imaging to assess glandular parenchymal architecture
- Dynamic endocrine stimulation testing (Cosyntropin/ACTH stimulation test, Dexamethasone suppression test, GnRH test)
Clinical Citations & Primary Literature (1)
- [1]Endocrine Society Clinical Practice Guideline for Testosterone Therapy in Men - Journal of Clinical Endocrinology & Metabolism (2021). PMID: 29562364
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Total Testosterone (Total T) into overall healthspan optimization.